Metabolic Dysfunction-Associated Steatotic Liver Disease: An Update on Screening and Therapeutic Options
Medicina Interna · 06.12.2023
DOI: 10.24950/rspmi.2522 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicina Interna, erschienen am 06.12.2023. Verfasst von Luis Gabriel de Melo Fernandes und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common forms of chronic liver disease, particularly associated with obesity and type 2 diabetes mellitus. The prevalence has been increasing in recent years, currently affecting around 25% of the world's population. The hallmark of its pathophysiology lies in insulin resistance and the accumulation of fat inside hepatocytes. Several clinical scores allow cost-effective screening, such as FIB-4 and NFS. Although it is considered the gold standard, liver biopsy can often be avoided by using hepatic elastography. Numerous drugs used in diabetes have therapeutic potential in metabolic dysfunction-associated steatotic liver disease, with the most studied class being GLP-1 receptor agonists. The bidirectional pathophysiological as-sociation between metabolic dysfunction-associated steatotic liver disease and diabetes will enable the development of this field and the emergence of new therapies.
Schlagwörter
Zitieren
APA
Fernandes, L. G. D. M., Castro, O. D., Sofia, Santos, S. S., Ferreira, G., Sérgio, Andrade, Luís, Henriques, & Cátia (2023). Metabolic Dysfunction-Associated Steatotic Liver Disease: An Update on Screening and Therapeutic Options. Medicina Interna. https://doi.org/10.24950/rspmi.2522
Vancouver
Fernandes LGDM, Castro OD, Sofia, Santos SS, Ferreira G, Sérgio, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease: An Update on Screening and Therapeutic Options. Medicina Interna. 2023. doi:10.24950/rspmi.2522
BibTeX
@article{Fernandes2023,
author = {Fernandes, Luis Gabriel de Melo and Castro, Osório De and Sofia and Santos, Sara S. and Ferreira, Gomes and Sérgio and Andrade and Luís and Henriques and Cátia},
title = {Metabolic Dysfunction-Associated Steatotic Liver Disease: An Update on Screening and Therapeutic Options},
journal = {Medicina Interna},
year = {2023},
doi = {10.24950/rspmi.2522}
}
EUVIMED